Core Viewpoint - Huajian Medical (01931) has seen a significant stock increase of over 13% following the announcement of a conditional agreement to acquire a 20.31% stake in Guofu Quantum for approximately HKD 3.142 billion, which will be paid through the issuance of shares. This acquisition aims to enhance capital synergy and establish an innovative cooperative network to support the globalization of Chinese assets [1][2]. Group 1 - Huajian Medical's stock rose by 13.31% to HKD 10.98, with a trading volume of HKD 45.6534 million [1]. - The acquisition of Guofu Quantum will make Huajian Medical the major shareholder, aiming to strengthen capital collaboration and broaden institutional cooperation [1]. - The company has launched several strategic initiatives since late July, including the "NewCo+RWA" exchange strategy and the issuance of IVDD stablecoins [2]. Group 2 - Huajian Medical's U.S. subsidiary is pursuing a stablecoin license, and the company has partnered with BGI's Huada Gongying to establish the world's first "innovative drug intellectual property tokenization fund" [2]. - The company announced the initiation of a "global enhanced Ethereum (ETH) treasury" strategy and completed a compliant purchase of HKD 149 million in ETH [2]. - Huajian Medical is seeking shareholder approval for a HKD 3 billion ETH purchase authorization to support the ecosystem construction of the medical innovative drug RWA trading platform [2].

Group 1 - Huajian Medical (01931) shares rose over 13%, reaching 10.98 HKD with a trading volume of 45.65 million HKD [1] - The company announced a conditional agreement to acquire 20.31% of Guofu Quantum's shares for approximately 3.142 billion HKD, to be paid through the issuance of consideration shares [1] - This acquisition aims to enhance capital synergy, promote the implementation of RWA ecosystem, and build an innovative cooperation network to support the globalization of Chinese assets [1] Group 2 - Since late July, Huajian Medical has launched several key strategic initiatives, including the introduction of the "NewCo+RWA" exchange strategy and the issuance of IVDD stablecoins [2] - The company is pursuing a stablecoin license for its U.S. subsidiary and has partnered with BGI's subsidiary to establish the world's first "innovative drug intellectual property tokenization fund" [2] - On August 8, Huajian Medical initiated the "Global Enhanced Ethereum (ETH) Treasury" strategy, collaborating with licensed exchange HashKey and completing a compliant purchase of 149 million HKD in ETH [2] - The company is seeking shareholder approval for a 3 billion HKD ETH purchase authorization to provide value anchoring and revenue feedback mechanisms for the RWA trading platform [2]

Core Viewpoint - 华检医疗's stock price increased by over 16%, reaching 9.64 HKD, with a trading volume of 29.15 million HKD, following the announcement of a board meeting scheduled for August 29, 2025, to discuss mid-term performance and potential dividend payments [1] Group 1 - The company has launched several key strategic initiatives since late July, including the introduction of the "NewCo+RWA" exchange strategy and the issuance of IVDD stablecoins [1] - The company is pushing its U.S. subsidiary to apply for a stablecoin license and has partnered with BGI's subsidiary to establish the world's first "Innovative Drug Intellectual Property Tokenization Fund" [1] - On August 8, the company announced the launch of a "Global Enhanced Ethereum (ETH) Treasury" strategy and completed the compliant purchase of 149 million HKD in ETH in collaboration with licensed exchange HashKey [1] Group 2 - The company is seeking shareholder approval for a 3 billion HKD ETH purchase authorization to provide value anchoring and revenue feedback mechanisms for the medical innovative drug RWA trading platform ecosystem [1]

Core Viewpoint - Huajian Medical (01931) has seen a significant stock price increase, rising over 16% in the afternoon trading session, attributed to strategic initiatives and upcoming financial announcements [1] Group 1: Stock Performance - As of the latest update, Huajian Medical's stock price is reported at 9.64 HKD, with a trading volume of 29.1585 million HKD [1] Group 2: Strategic Initiatives - The company announced a board meeting scheduled for August 29, 2025, to consider and approve the mid-term performance for the six months ending June 30, 2025, and to discuss potential interim dividends [1] - Since late July, Huajian Medical has launched several key strategic initiatives, including the introduction of the "NewCo+RWA" exchange strategy and the issuance of IVDD stablecoins [1] - The company is pushing its U.S. subsidiary to apply for a stablecoin license and has partnered with BGI's subsidiary to establish the world's first "Innovative Drug Intellectual Property Tokenization Fund" [1] - On August 8, Huajian Medical officially launched the "Global Enhanced Ethereum (ETH) Treasury" strategy, collaborating with the licensed exchange HashKey and completing a compliant purchase of 149 million HKD in ETH [1] - Recently, the company is seeking shareholder approval for a 3 billion HKD ETH purchase authorization to provide value anchoring and revenue feedback mechanisms for the medical innovation drug RWA trading platform [1]

Core Viewpoint - Xinhua Medical (600587.SH) is strategically focusing on innovation and collaboration with its investee company, Huajian Medical (01931), which it holds a 27.29% stake in, indicating a significant shift towards a new business model in the medical sector [1][4]. Group 1: Investment Structure and Strategic Collaboration - Xinhua Medical holds 443.7 million shares of Huajian Medical through its wholly-owned subsidiary, Hualun International, and uses the equity method to account for investment income [4]. - The company has appointed two directors to participate in Huajian Medical's board of 11 members, emphasizing its commitment to strategic oversight [4]. - Xinhua Medical has expressed a strong focus on industry risks and opportunities, providing credibility to Huajian Medical's innovative path [4]. Group 2: Strategic Developments of Huajian Medical - Since July, Huajian Medical has undergone a strategic upgrade centered on "reconstructing the medical innovation asset chain," initiating a dual primary listing in the U.S. [4]. - Key initiatives launched include the "NewCo+RWA" exchange strategy and the issuance of IVDD stablecoins, along with a partnership to establish a tokenized fund for innovative drug intellectual property [4][5]. - In August, Huajian Medical accelerated its strategy by launching a global enhanced Ethereum (ETH) treasury and forming a strategic partnership with HashKey, completing a compliant purchase of 149 million HKD in ETH [5]. Group 3: Market Impact and Future Prospects - The strategic moves aim to address pain points in pharmaceutical innovation by leveraging blockchain technology for intellectual property rights, pricing, and cross-border transactions [5]. - Xinhua Medical's cautious stance suggests potential strategic collaboration opportunities with Huajian Medical regarding its U.S. IPO, with the value of Xinhua Medical's stake in Huajian Medical reaching 4.1 billion HKD based on a market valuation of 15 billion HKD [5][6]. - The integration of stablecoins, Ethereum, and the RWA exchange is expected to create a multi-layered value system that could reshape traditional pharmaceutical intellectual property trading [6][7].

Group 1 - The core strategy of the company is to launch a "Global Enhanced Ethereum Vault" with a downward protection mechanism, designating Ethereum (ETH) as a strategic reserve asset [2][6] - The company has entered into a strategic partnership with HashKey Group, which will provide support for large-scale ETH transactions, cost optimization, and liquidity in global markets [6][9] - The company has invested 149 million HKD to purchase 5,190 ETH and plans to continue increasing its holdings through a dollar-cost averaging strategy, with an approved budget of 880 million HKD [6][11] Group 2 - The "Active Coin Generation" feature is a key highlight of the company's Ethereum Vault strategy, allowing for the tokenization of innovative drug intellectual property (RWA) and trading on the ivd.xyz exchange [9][10] - The downward protection mechanism includes various strategies such as ATM mechanisms, priority structures, and price buyback commitments to ensure investor safety [10][11] - The company aims to replicate the success of MicroStrategy and Metaplanet by leveraging its Ethereum holdings to achieve significant market capitalization growth, with a target to exceed 100 billion HKD in two years [11][13] Group 3 - The company's Web3 exchange ecosystem and Ethereum Vault strategy create a new paradigm for financing, circulation, and revenue distribution in innovative drug development [13] - This approach aligns with the Hong Kong Monetary Authority's policy for efficient cross-border asset circulation and supports China's strategy for innovative drug commercialization [13] - The company aims to provide a compliant and transparent Web3 entry point for retail investors and patients, accelerating the availability of critical medications globally [13]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 IVD Medical Holding Limited 華檢醫療控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1931） 自願性公告 打 造「全 球 增 強 版 以 太 坊（ETH）金 庫」、升 維 公 司 全 球 戰 略、為 生 態 參 與 者創造價值 本 公 告 由 華 檢 醫 療 控 股 有 限 公 司（「本公司」或「華檢醫療」，連 同 其 附 屬 公 司 統 稱「本集團」）董 事 會（「董事會」）自 願 作 出，旨 在 向 股 東、潛 在 投 資 者 及 市 場 各 方 全 面 闡 述 本 集 團 最 新 戰 略 升 級 暨 升 維 舉 措－經 董 事 會 決 議 通 過，本 集 團 正 式 啟 動「具 備 下 行 保 護 機 制 的 全 球 增 強 版 以 太 坊（ETH）金 庫」戰 略（「以 太 坊（ETH） 金庫戰略」） ...

Core Viewpoint - The stablecoin industry is transitioning from "concept exploration" to "compliance implementation," with a focus on regulatory clarity and the establishment of a full industry chain in the Hong Kong stock market, where nearly 20 stablecoin concept stocks are involved [1]. Group 1: Business Positioning - Hong Kong stablecoin concept stocks generally focus on cross-border payments and broad RWA applications, with a "breadth-first" business model [2]. - In contrast, Huajian Medical's IVDD stablecoin adopts a "depth-first" strategy, concentrating on high-barrier medical innovation assets, including gene therapies and targeted drugs [3]. Group 2: Technical Architecture - Most Hong Kong stablecoin concept stocks utilize a "public chain + smart contract" generic architecture [4]. - Huajian Medical's IVDD employs a "hybrid architecture + deep adaptation to medical scenarios," enhancing asset tokenization precision and efficiency [6][7]. Group 3: Compliance Pathways - Hong Kong stablecoin concept stocks exhibit a "license-driven" compliance approach, with companies like Guotai Junan International obtaining licenses to provide stablecoin trading services [8][9]. - Huajian Medical's IVDD follows a "license + ecosystem" dual-driven model, applying for a stablecoin license while building a medical data flow platform [10]. Group 4: Ecological Value - Most Hong Kong stablecoin concept stocks are positioned as "payment tools," focusing on facilitating transactions [11][12]. - Huajian Medical's IVDD aims to be a "medical industry innovator," enhancing asset liquidity and potentially transforming the medical asset value ecosystem [13]. Group 5: Future Outlook - The implementation of Hong Kong's Stablecoin Regulation and the advancement of the U.S. GENIUS Act will lead to differentiation among Hong Kong stablecoin concept stocks [14]. - Huajian Medical's IVDD, as a pioneer in medical RWA, is expected to replicate successful financing models and expand its asset management scale significantly [15][16].